| scholarly article | Q13442814 |
| P50 | author | Roland E. Schmieder | Q57071845 |
| P2093 | author name string | Stefanie Friedrich | |
| P2860 | cites work | Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients | Q28236175 |
| Cardiorenal end points in a trial of aliskiren for type 2 diabetes | Q28278569 | ||
| Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial | Q38454911 | ||
| Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure | Q43266277 | ||
| Hypotension and ischaemic stroke associated with aliskiren in the ALTITUDE trial: sensitisation of the Bezold-Jarisch reflex? | Q43591328 | ||
| Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). | Q44205751 | ||
| Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. | Q44372640 | ||
| Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren | Q44642058 | ||
| Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators | Q45165979 | ||
| Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy | Q46157336 | ||
| Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design | Q46162422 | ||
| Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide | Q46165937 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans | Q46535584 | ||
| Aliskiren combined with losartan in type 2 diabetes and nephropathy | Q46558669 | ||
| Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats | Q46652759 | ||
| Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE ( | Q57396224 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 193-196 | |
| P577 | publication date | 2013-07-19 | |
| P1433 | published in | Journal of the Renin-Angiotensin-Aldosterone System | Q6296180 |
| P1476 | title | Review of direct renin inhibition by aliskiren | |
| P478 | volume | 14 |
| Q89827956 | Aliskiren and the dual complement inhibition concept |
| Q47369456 | Aliskiren protects against myocardial ischaemia-reperfusion injury via an endothelial nitric oxide synthase dependent manner |
| Q38444730 | Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications |
| Q34221347 | Comparative evaluation of aliskiren, ramipril, and losartan on psychomotor performance in healthy volunteers: A preliminary report |
| Q37671457 | Increasing complexity: which drug class to choose for treatment of hypertension in the elderly? |
| Q39018887 | The Renin Angiotensin Aldosterone System in Obesity and Hypertension: Roles in the Cardiorenal Metabolic Syndrome |
Search more.